We are live on ! Find out more
Abingworth

Abingworth Portfolio holdings

AUM $304M Turnover 0%
1-Year Est. Return 95.02%
This Fund
S&P 500
This Quarter Est. Return
+10.64%
1 Year Est. Return
+95.02%
3 Year Est. Return
+186.67%
5 Year Est. Return
+346.26%
10 Year Est. Return
–
AUM
$130M
AUM Growth
–
Cap. Flow
+$129M
Cap. Flow %
99.53%
Top 10 Hldgs %
99.79%
Holding
11
New
11
Increased
–
Reduced
–
Closed
–
Avg Time Held
0 years
Top 10 Avg Time Held
0 years
Top 20 Avg Time Held
0 years

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 98.74%
2 Miscellaneous 1.26%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
AMRN icon
1
Amarin
AMRN
$450M
$46.8M 36.03%
+404,374
New +$55.8M
2013 Q2
0 quarters
PTLA
2
DELISTED
Portola Pharmaceuticals
PTLA
$30.5M 23.47%
+1,240,917
New +$24.7M
2013 Q2
0 quarters
SUPN icon
3
DELISTED
Supernus Pharmaceuticals
SUPN
$23.2M 17.84%
+3,600,000
New +$21.2M
2013 Q2
0 quarters
ALNY icon
4
Alnylam Pharmaceuticals
ALNY
$19.6B
$9.7M 7.45%
+313,053
New +$8.33M
2013 Q2
0 quarters
QUIT icon
5
Achieve Life Sciences
QUIT
$617M
$5.92M 4.55%
+274
New +$6.13M
2013 Q2
0 quarters
CEMP
6
DELISTED
Cempra
CEMP
$5.59M 4.3%
+714,285
New +$4.94M
2013 Q2
0 quarters
ZGNX
7
DELISTED
Zogenix
ZGNX
$4.02M 3.09%
+291,902
New +$3.74M
2013 Q2
0 quarters
ANTH
8
DELISTED
Anthera Pharmaceuticals
ANTH
$1.73M 1.33%
+54,749
New +$2.04M
2013 Q2
0 quarters
HPTX
9
DELISTED
Hyperion Therapeutics
HPTX
$1.38M 1.06%
+62,500
New +$1.37M
2013 Q2
0 quarters
GWPH
10
DELISTED
GW Pharmaceuticals
GWPH
$879K 0.68%
+102,200
New +$905K
2013 Q2
0 quarters
ZLCS
11
DELISTED
Zalicus
ZLCS
$268K 0.21%
+78,967
New +$283K
2013 Q2
0 quarters

Similar funds

Abingworth's Q2 2013 Portfolio in Review

Q2 2013 is the first quarter with a 13F filing on record for Abingworth, which disclosed 11 positions worth $130M. Its ten largest holdings account for 100% of the portfolio.

Its largest position is Amarin: 404,374 shares worth $46.8M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, followed by Miscellaneous.

  • Abingworth's largest Q2 2013 buy was Amarin: 404,374 shares worth $46.8M.
  • Abingworth's ten largest holdings make up 100% of its $130M portfolio in Q2 2013.
  • Abingworth disclosed 11 positions in Q2 2013, its first 13F filing on record.

Based on Abingworth's 13F filing for Q2 2013, filed 14 Aug 2013.